[Asia Economy Reporter Hyungsoo Park] Bukuk Securities analyzed on the 11th that Medipost has signed a contract to transfer the high-efficiency cell culture platform technology MLSC to LG Chem.
Researcher Hyoseop Shin of Bukuk Securities explained, "It is the right to develop cell and gene therapies by combining the next-generation platform technology MLSC with LG Chem's gene editing technology," adding, "It includes commercialization rights for overseas markets excluding Japan and China, and exclusive development rights for specific genes developed by LG Chem."
He continued, "The total contract size is 427.8 billion KRW with a non-refundable signing fee of 1 billion KRW, milestone payments of 426.8 billion KRW received at development, regulatory approval, and sales stages, and a separate structure for receiving running royalties."
Researcher Shin emphasized, "This is a concrete outcome derived from the joint research conducted by LG Chem and Medipost for about two years since December 2018 to develop cell and gene therapies."
He introduced, "The MLSC technology transferred is part of the next-generation high-efficiency stem cell mass production platform SMUP," adding, "It is a technology that selects small-sized high-efficiency stem cells and creates a specific environment to culture stem cells."
Furthermore, he explained, "The core technology of the cell and gene therapies that LG Chem aims to develop is gene insertion efficiency and maintaining the stability and activity of cells," stating, "Because the gene delivery vector enters the target cells or tissues, activates the therapeutic gene, and thus therapeutic effects can be expected."
Researcher Shin said, "The contract proved that Medipost's SMUP platform can expand not only to stem cell therapies but also to cell and gene therapies," adding, "There is also a joint development option where Medipost can participate as a co-developer depending on clinical results."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
